BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

272 related articles for article (PubMed ID: 20112342)

  • 1. ADAM28 is a serological and histochemical marker for non-small-cell lung cancers.
    Kuroda H; Mochizuki S; Shimoda M; Chijiiwa M; Kamiya K; Izumi Y; Watanabe M; Horinouchi H; Kawamura M; Kobayashi K; Okada Y
    Int J Cancer; 2010 Oct; 127(8):1844-56. PubMed ID: 20112342
    [TBL] [Abstract][Full Text] [Related]  

  • 2. ADAM8 as a novel serological and histochemical marker for lung cancer.
    Ishikawa N; Daigo Y; Yasui W; Inai K; Nishimura H; Tsuchiya E; Kohno N; Nakamura Y
    Clin Cancer Res; 2004 Dec; 10(24):8363-70. PubMed ID: 15623614
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Serum matrix metalloproteinases -2, -9 and tissue inhibitors of metalloproteinases -1, -2 in lung cancer--TIMP-1 as a prognostic marker.
    Ylisirniö S; Höyhtyä M; Turpeenniemi-Hujanen T
    Anticancer Res; 2000; 20(2B):1311-6. PubMed ID: 10810441
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prospective study of urinary and serum cross-linked N-telopeptide of type I collagen (NTx) for diagnosis of bone metastasis in patients with lung cancer.
    Tamiya M; Tokunaga S; Okada H; Suzuki H; Kobayashi M; Sasada S; Okamoto N; Morishita N; Matsuura Y; Miyamoto N; Hattori M; Taira K; Daga H; Takeda K; Hirashima T
    Clin Lung Cancer; 2013 Jul; 14(4):364-9. PubMed ID: 23276824
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Baseline and decline of serum ADAM28 during chemotherapy of advanced non-small cell lung cancer: a probable predictive and prognostic factor.
    Lv YL; Yuan DM; Wang QB; Zhan P; Luo L; Lv TF; Liu HB; Li YF; Wen J; Song Y
    Med Oncol; 2012 Dec; 29(4):2633-9. PubMed ID: 22354764
    [TBL] [Abstract][Full Text] [Related]  

  • 6. miR-1254 and miR-574-5p: serum-based microRNA biomarkers for early-stage non-small cell lung cancer.
    Foss KM; Sima C; Ugolini D; Neri M; Allen KE; Weiss GJ
    J Thorac Oncol; 2011 Mar; 6(3):482-8. PubMed ID: 21258252
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Circulating DNA is a useful prognostic factor in patients with advanced non-small cell lung cancer.
    Sirera R; Bremnes RM; Cabrera A; Jantus-Lewintre E; Sanmartín E; Blasco A; Del Pozo N; Rosell R; Guijarro R; Galbis J; Sánchez JJ; Camps C
    J Thorac Oncol; 2011 Feb; 6(2):286-90. PubMed ID: 21252717
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A multiparametric serum kallikrein panel for diagnosis of non-small cell lung carcinoma.
    Planque C; Li L; Zheng Y; Soosaipillai A; Reckamp K; Chia D; Diamandis EP; Goodglick L
    Clin Cancer Res; 2008 Mar; 14(5):1355-62. PubMed ID: 18316555
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Circulating serum vascular endothelial growth factor is not a prognostic factor of non-small cell lung cancer.
    Chakra M; Pujol JL; Lamy PJ; Bozonnat MC; Quantin X; Jacot W; Daurès JP
    J Thorac Oncol; 2008 Oct; 3(10):1119-26. PubMed ID: 18827607
    [TBL] [Abstract][Full Text] [Related]  

  • 10. ADAM28 is overexpressed in human non-small cell lung carcinomas and correlates with cell proliferation and lymph node metastasis.
    Ohtsuka T; Shiomi T; Shimoda M; Kodama T; Amour A; Murphy G; Ohuchi E; Kobayashi K; Okada Y
    Int J Cancer; 2006 Jan; 118(2):263-73. PubMed ID: 16052521
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Epithelial-specific methylation marker: a potential plasma biomarker in advanced non-small cell lung cancer.
    Vinayanuwattikun C; Sriuranpong V; Tanasanvimon S; Chantranuwat P; Mutirangura A
    J Thorac Oncol; 2011 Nov; 6(11):1818-25. PubMed ID: 21964525
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Elevated expression of BIRC6 protein in non-small-cell lung cancers is associated with cancer recurrence and chemoresistance.
    Dong X; Lin D; Low C; Vucic EA; English JC; Yee J; Murray N; Lam WL; Ling V; Lam S; Gout PW; Wang Y
    J Thorac Oncol; 2013 Feb; 8(2):161-70. PubMed ID: 23287853
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical value of p53, c-erbB-2, CEA and CA125 regarding relapse, metastasis and death in resectable non-small cell lung cancer.
    Pollán M; Varela G; Torres A; de la Torre M; Ludeña MD; Ortega MD; Pac J; Freixenet J; Gómez G; Sebastián F; Díez M; Arrabal R; Canalís E; García-Tirado J; Arnedillo A; Rivas JJ; Minguella J; Gómez A; García M; Aragonés N; Pérez-Gómez B; López-Abente G; González-Sarmiento R; Rojas JM
    Int J Cancer; 2003 Dec; 107(5):781-90. PubMed ID: 14566828
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Serum Human Epididymis Secretory Protein 4 (HE4) is a Potential Prognostic Biomarker in Non-Small Cell Lung Cancer.
    Mo D; He F
    Clin Lab; 2018 Sep; 64(9):1421-1428. PubMed ID: 30274019
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical usefulness of serum cytokeratin 19 fragment as a tumor marker for lung cancer.
    Maeda Y; Segawa Y; Takigawa N; Takata I; Fujimoto N
    Intern Med; 1996 Oct; 35(10):764-71. PubMed ID: 8933183
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Serum anti-p53 autoantibodies in primary resected non-small-cell lung carcinoma.
    Iizasa T; Fujisawa T; Saitoh Y; Hiroshima K; Ohwada H
    Cancer Immunol Immunother; 1998 Aug; 46(6):345-9. PubMed ID: 9756419
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of histologic type and smoking status on interpretation of serum carcinoembryonic antigen value in non-small cell lung carcinoma.
    Okada M; Nishio W; Sakamoto T; Uchino K; Yuki T; Nakagawa A; Tsubota N
    Ann Thorac Surg; 2004 Sep; 78(3):1004-9; discussion 1009-10. PubMed ID: 15337038
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Evaluation of the relationship between serum carcinoembryonic antigen level and treatment outcome in surgically resected clinical-stage I patients with non-small-cell lung cancer.
    Hotta K; Segawa Y; Takigawa N; Kishino D; Saeki H; Nakata M; Mandai K; Eguchi K
    Anticancer Res; 2000; 20(3B):2177-80. PubMed ID: 10928173
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Soluble Programmed Cell Death Ligand 1 as a Novel Biomarker for Nivolumab Therapy for Non-Small-cell Lung Cancer.
    Okuma Y; Wakui H; Utsumi H; Sagawa Y; Hosomi Y; Kuwano K; Homma S
    Clin Lung Cancer; 2018 Sep; 19(5):410-417.e1. PubMed ID: 29859759
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prognostic significance of TAZ expression in resected non-small cell lung cancer.
    Xie M; Zhang L; He CS; Hou JH; Lin SX; Hu ZH; Xu F; Zhao HY
    J Thorac Oncol; 2012 May; 7(5):799-807. PubMed ID: 22481233
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.